<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04056689</url>
  </required_header>
  <id_info>
    <org_study_id>DNLI-C-0003</org_study_id>
    <nct_id>NCT04056689</nct_id>
  </id_info>
  <brief_title>Study to Evaluate DNL151 in Subjects With Parkinson's Disease</brief_title>
  <official_title>A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL151 in Subjects With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Denali Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Denali Therapeutics Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and&#xD;
      pharmacodynamics of multiple oral doses of DNL151 in subjects with Parkinson's disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 23, 2019</start_date>
  <completion_date type="Actual">December 2, 2020</completion_date>
  <primary_completion_date type="Actual">December 2, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects with Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Randomization to Day 42</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects with laboratory test abnormalities</measure>
    <time_frame>Randomization to Day 42</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects with vital sign abnormalities</measure>
    <time_frame>Randomization to Day 42</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects with electrocardiogram (ECG) abnormalities</measure>
    <time_frame>Randomization to Day 42</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects with clinically significant neurological examination abnormalities</measure>
    <time_frame>Randomization to Day 42</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic measure of maximum observed plasma concentration (Cmax) of DNL151</measure>
    <time_frame>Randomization to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic measure of time to reach maximum observed plasma concentration (Tmax) of DNL151</measure>
    <time_frame>Randomization to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic measure of trough plasma observed concentration (Ctrough) of DNL151</measure>
    <time_frame>Randomization to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic measure of area under the plasma drug concentration-time curve (AUC) of DNL151</measure>
    <time_frame>Randomization to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic measure of CSF concentrations of DNL151</measure>
    <time_frame>Randomization to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic measure of pS935 in whole blood</measure>
    <time_frame>Randomization to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic measure of pRab10 in PBMCs</measure>
    <time_frame>Randomization to Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>DNL151 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DNL151 Mid Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DNL151 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DNL151</intervention_name>
    <description>Oral repeating dose</description>
    <arm_group_label>DNL151 High Dose</arm_group_label>
    <arm_group_label>DNL151 Low Dose</arm_group_label>
    <arm_group_label>DNL151 Mid Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral repeating dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI) between 18 and 35.0 kg/m2, inclusive&#xD;
&#xD;
          -  Clinical diagnosis of Parkinson's disease meeting UK Brain Bank criteria and H&amp;Y Stage&#xD;
             I, II, or III.&#xD;
&#xD;
          -  Able to hold Parkinson's disease medications 8 hours (overnight) prior to specific&#xD;
             study assessments&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any history of clinically significant asthma, chronic obstructive pulmonary disease,&#xD;
             or emphysema within 5 years of screening, or other clinically significant pulmonary&#xD;
             disease within 6 months of screening&#xD;
&#xD;
          -  Abnormal Vitals including Respiratory Rate, Body Temperature, Blood Pressure, and&#xD;
             Pulse Rate&#xD;
&#xD;
          -  Pulmonary Function Tests (PFTs) (FVC &lt;60% predicted, FEV1 &lt;50% predicted, FEV1:FVC&#xD;
             ratio &lt;0.6, DLCO &lt;70% predicted)&#xD;
&#xD;
          -  Clinically significant neurologic disorder other than Parkinson's disease, including&#xD;
             history of stroke within 12 months of screening, cognitive impairment, seizure within&#xD;
             5 years of screening, or head trauma with loss of consciousness within 6 months of&#xD;
             screening&#xD;
&#xD;
          -  Montreal Cognitive Assessment (MoCA) score of &lt;24 at screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andr√©s Cruz-Herranz</last_name>
    <role>Study Director</role>
    <affiliation>Denali Therapeutics Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PPD Clinical Research Unit</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quest Research Institute</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Human Drug Research</name>
      <address>
        <city>Leiden</city>
        <state>South Holland</state>
        <zip>2333</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QPS</name>
      <address>
        <city>Leeuwarden</city>
        <zip>8934AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MAC Clinical Research</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9NQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simbec-Orion Clinical Pharmacology</name>
      <address>
        <city>Merthyr Tydfil</city>
        <zip>CF48 4DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 12, 2019</study_first_submitted>
  <study_first_submitted_qc>August 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2019</study_first_posted>
  <last_update_submitted>January 15, 2021</last_update_submitted>
  <last_update_submitted_qc>January 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LRRK2</keyword>
  <keyword>Movement Disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

